Newly Synthesized Benzimidazoles Inhibit Vascular Endothelial Growth Factor and Matrix Metalloproteinase-2 and-9 Levels in Prostate Cancer Cells
| dc.contributor.author | Ilhan, S | |
| dc.contributor.author | Dilekci, G | |
| dc.contributor.author | Guner, A | |
| dc.contributor.author | Bektas, H | |
| dc.date.accessioned | 2025-04-10T10:33:00Z | |
| dc.date.available | 2025-04-10T10:33:00Z | |
| dc.description.abstract | Background: Investigating the effects of newly synthesized agents on various molecular mechanisms to understand their mechanism of action is an important step of pre-clinical screening. Benzimidazoles are composed of a unique fused benzene and imidazole ring and have attracted great attention due to their broad bioactivities, including antitumor. Objective: In the current study, we reported the synthesis of novel benzimidazole derivatives and investigated the possible cytotoxic and anti-angiogenic effects on human prostate cancer and umbilical vein endothelial cells (HUVECs). Methods: MTT assay was used to assess cell viability. A scratch assay was conducted to monitor the migration of cells. mRNA expression levels of VEGF, MMP-2, and MMP-9 were evaluated using qPCR. Changes in protein levels were evaluated by western blotting. Results: Compound G1, having a chlorine moiety, showed a potent cytotoxic activity on both prostate cancer cells and HUVECs, and inhibited cell migration via decreasing the mRNA and protein levels of key angiogenesis-related molecules such as VEGF, MMP-2, and MMP-9. Conclusion: These results suggest that newly synthesized G1 may be a novel anti-angiogenic agent for prostate cancer treatment. | |
| dc.identifier.e-issn | 1875-5992 | |
| dc.identifier.issn | 1871-5206 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/39337 | |
| dc.language.iso | English | |
| dc.title | Newly Synthesized Benzimidazoles Inhibit Vascular Endothelial Growth Factor and Matrix Metalloproteinase-2 and-9 Levels in Prostate Cancer Cells | |
| dc.type | Article |